Accord Gets First EU-Wide Nod For Xarelto Rival
But Originator Bayer Claims Xarelto Patent Protection Until 2023
Accord Healthcare has garnered the first positive opinion recommending granting a pan-European marketing authorization for a generic version of rivaroxaban from the EMA’s CHMP. However, originator Bayer claims that no generic competition will be possible for another three years.
